Nutriband Stock (NASDAQ:NTRB)
Previous Close
$4.21
52W Range
$1.53 - $9.60
50D Avg
$5.95
200D Avg
$4.03
Market Cap
$49.16M
Avg Vol (3M)
$31.62K
Beta
0.42
Div Yield
-
NTRB Company Profile
Nutriband Inc. develops a portfolio of transdermal pharmaceutical products. The company's lead product in development is AVERSA fentanyl, an abuse deterrent fentanyl transdermal system that provides clinicians and patients with an extended-release transdermal fentanyl product for use in managing chronic pain requiring around the clock opioid therapy. It also develops other products, which include AVERSA buprenorphine and AVERSA methylphenidate; exenatide for type 2 diabetes; and follicle stimulating hormone for infertility. Nutriband Inc. has a license agreement with Rambam Med-Tech Ltd. for the development of the RAMBAM Closed System Transfer Devices. The company was incorporated in 2016 and is headquartered in Orlando, Florida.
NTRB Performance
Peer Comparison
| Ticker | Company |
|---|---|
| CYT | Cyteir Therapeutics, Inc. |
| LGVN | Longeveron Inc. |
| QNRX | Quoin Pharmaceuticals, Ltd. |
| CSBR | Champions Oncology, Inc. |
| HCWB | HCW Biologics Inc. |
| VRAX | Virax Biolabs Group Limited |
| MNOV | MediciNova, Inc. |
| RNXT | RenovoRx, Inc. |
| RZLT | Rezolute, Inc. |
| INDP | Indaptus Therapeutics, Inc. |
| TPST | Tempest Therapeutics, Inc. |
| ANEB | Anebulo Pharmaceuticals, Inc. |
| MOLN | Molecular Partners AG |
| FBRX | Forte Biosciences, Inc. |
| ELYM | Eliem Therapeutics, Inc. |